Onconetix, Inc.
Onconetix develops Proclarix, an in vitro diagnostic test for prostate cancer approved in the European Union.
8-KSep 14Latest SEC filing, period to Sep 8
Sep 14Latest story
August 2026
July 2026
Sign inSign inOnconetix develops Proclarix, an in vitro diagnostic test for prostate cancer approved in the European Union.